Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05714969 · ClinicalTrials.gov registry record · Phase 2
A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
A Phase 2 study of Thrombotic Thrombocytopenic Purpura (TTP), sponsored by Takeda.
- Active
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 20
- Study locations
NCT05714969: Active Phase 2 study of Thrombotic Thrombocytopenic Purpura (TTP), sponsored by Takeda.
NCT05714969 is a Phase 2 study of Thrombotic Thrombocytopenic Purpura (TTP) that is active but no longer recruiting, run by Takeda. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05714969, a Phase 2 study of Thrombotic Thrombocytopenic Purpura (TTP), is active but no longer recruiting, sponsored by Takeda.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study of TAK-755 in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP). The main aim of this study is to determine the percentage of participants with a clinical (Part 1) or platelet (Part 2) response without plasma exchange during the study. Participants who have an acute attack of iTTP will receive TAK-755 and immunosuppressive therapy during their stay at the hospital until they achieve a clinical response in Part 1 or platelet response in Part 2. Participants will also be treated with TAK-755 for an additional time of up to 6 weeks after the acute phase. In total, participants will stay in the study for approximately 3 months.
Primary Outcome
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. SAE: Signs, symptoms or outcomes which results in death, requires i
Conditions Studied
Interventions
- BIOLOGICAL TAK-755
Study Locations (20)
Other
- AKH - Medizinische Universitat Wien - Vienna
- General Hospital of Thessaloniki "G. Papanikolaou" - Thessaloniki
- Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico - Milan
- Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino - Torino
- Hospital General Universitario Gregorio Maranon - Madrid
- Hospital Universitari i Politecnic La Fe - Valencia
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
North Carolina
- Duke University Medical Center - Durham
- Leo Jenkins Cancer Center/ECU School of Medicine - Greenville
Florida
- University of Florida - Shands - Gainesville
Minnesota
- University of Minnesota Clinical Research Unit - Minneapolis
New Jersey
- Rutgers University - New Brunswick
New York
- Weill Cornell - New York
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-03-21 |
| Est. Completion | 2026-06-11 |
| Phase | Phase 2 |
What the registry record for NCT05714969 still lists
NCT05714969 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Thrombotic Thrombocytopenic Purpura (TTP) appearing as the primary indexed condition, and to 1 intervention - of which TAK-755 is the first listed.
NCT05714969 names 20 study sites across 12 states, led by Other, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05714969 about?
NCT05714969 is a clinical study titled "A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)". This is a study of TAK-755 in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP). The main aim of this study is to determine the percentage of participants with a clinical (Part 1) or platelet (Part 2) response without plasma exchange during the study. Participants who have an ac...
What is the current status of trial NCT05714969?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2023-03-21. Estimated completion is 2026-06-11.
What conditions does trial NCT05714969 study?
This clinical trial studies the following conditions: Thrombotic Thrombocytopenic Purpura (TTP).
What interventions are being tested in trial NCT05714969?
The interventions under investigation include: TAK-755 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05714969?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05714969 being conducted?
This trial has 20 study locations across Florida, Massachusetts, Minnesota, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombotic Thrombocytopenic Purpura (TTP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05714969's enrollment target sits among peer trials
33 1553rd of 2000 higher than 438 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI